Catheter-guided nanoparticle delivery of anti–PD-L1 immunotherapy to liver tumors
Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma
It delivers PD-L1 blocking immunotherapy directly into liver tumors through a catheter using nanoparticle carriers for people with hepatocellular carcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11294290 on NIH RePORTER |
What this research studies
If you had hepatocellular carcinoma, doctors would use a catheter threaded into the artery supplying your tumor to place tiny nanoparticle carriers holding anti–PD-L1 antibodies right at the cancer site. The nanoparticles are engineered so the antibodies sit in an oriented way that improves binding to the tumor and reduces off-target interactions with normal tissues. The plan is to pair this local delivery with tumor-directed treatments like ablation to boost immune response where it is needed most. Early work will be done in the lab and animal models to refine the approach before moving toward human applications if results are promising.
Who could benefit from this research
Good fit: Ideal candidates would be people with hepatocellular carcinoma who are not eligible for curative surgery or transplant and whose tumors can be reached by arterial catheterization.
Not a fit: Patients with tumors that cannot be accessed via the tumor-feeding artery, with widespread metastatic disease, or who cannot undergo arterial procedures may not benefit from this approach.
Why it matters
Potential benefit: This approach could strengthen immune attack on liver tumors while lowering systemic immune side effects seen with standard infusion of checkpoint drugs.
How similar studies have performed: Systemic PD-1/PD-L1 drugs have helped some HCC patients and combining checkpoint blockade with local ablation has shown promise, but catheter-based oriented nanoparticle delivery is relatively new and mainly at the preclinical stage.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Kim, Dong-Hyun — Northwestern University
- Study coordinator: Kim, Dong-Hyun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.